These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30069194)

  • 1. Does the timing of aspirin administration influence its antiplatelet effect - review of literature on chronotherapy.
    Miciak-Ławicka E; Begier-Krasińska B; Tykarski A; Krasiński Z
    Kardiochir Torakochirurgia Pol; 2018 Jun; 15(2):125-129. PubMed ID: 30069194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of nonsteroidal anti-inflammatory drugs on aspirin's antiplatelet effects and suggestion of the most suitable time for administration of both agents without resulting in interaction.
    Shibata K; Akagi Y; Nozawa N; Shimomura H; Aoyama T
    J Pharm Health Care Sci; 2017; 3():9. PubMed ID: 28293429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The first 3500 years of aspirin history from its roots - A concise summary.
    Montinari MR; Minelli S; De Caterina R
    Vascul Pharmacol; 2019 Feb; 113():1-8. PubMed ID: 30391545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet effect of acetylsalicylic acid, metamizole and their combination - in vitro and in vivo comparisons.
    Papp J; Sandor B; Vamos Z; Botor D; Toth A; Rabai M; Kenyeres P; Cseplo P; Juricskay I; Mezosi E; Koller A; Toth K
    Clin Hemorheol Microcirc; 2014; 56(1):1-12. PubMed ID: 23076007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [John Vane, 1927-2004, the pharmacologist of the vascular endothelium [corrected]].
    Chast F
    Ann Pharm Fr; 2006 Nov; 64(6):416-24. PubMed ID: 17119472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acetylsalicylic acid in the prevention and treatment of cardiovascular diseases].
    Łabuz-Roszak B; Horyniecki M; Łącka-Gaździk B
    Wiad Lek; 2018; 71(8):1608-1614. PubMed ID: 30684348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
    Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
    Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation.
    Patrick J; Dillaha L; Armas D; Sessa WC
    Postgrad Med; 2015 Aug; 127(6):573-80. PubMed ID: 25998572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aspirin throughout the ages: a historical review].
    Lévesque H; Lafont O
    Rev Med Interne; 2000 Mar; 21 Suppl 1():8s-17s. PubMed ID: 10763200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
    Schrör K
    Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus.
    Gurbel PA; Bliden KP; Chaudhary R; Patrick J; Liu F; Chen G; McLeod C; Tantry US
    Am J Cardiol; 2016 Dec; 118(12):1941-1947. PubMed ID: 27769511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical pharmacology of acetylsalicylic acid].
    Schröder H; Schrör K
    Z Kardiol; 1992; 81 Suppl 4():171-5. PubMed ID: 1290295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The isoflavonoid tectorigenin has better antiplatelet potential than acetylsalicylic acid.
    Applová L; Karlíčková J; Říha M; Filipský T; Macáková K; Spilková J; Mladěnka P
    Phytomedicine; 2017 Nov; 35():11-17. PubMed ID: 28991640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of platelet-vessel wall interactions by thromboxane receptor antagonism in a human in vitro system: potentiation of antiplatelet effects of aspirin.
    Escolar G; Albors M; Garrido M; Bioque G; Díaz Ricart M; Carretero M; Ordinas A
    Eur J Clin Invest; 1998 Jul; 28(7):562-8. PubMed ID: 9726037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE).
    Zeymer U; Hohlfeld T; Vom Dahl J; Erbel R; Münzel T; Zahn R; Roitenberg A; Breitenstein S; Pap ÁF; Trenk D
    Thromb Haemost; 2017 Feb; 117(3):625-635. PubMed ID: 28102427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of aspirin and two nitric oxide donors on the infarcted heart in situ.
    Yamamoto T; Kakar NR; Vina ER; Johnson PE; Bing RJ
    Life Sci; 2000 Jul; 67(7):839-46. PubMed ID: 10968413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects.
    Bode-Böger SM; Böger RH; Schubert M; Frölich JC
    Eur J Clin Pharmacol; 1998; 54(9-10):707-14. PubMed ID: 9923572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
    Guth BD; Müller TH
    Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits.
    Shinmura K; Kodani E; Xuan YT; Dawn B; Tang XL; Bolli R
    J Am Coll Cardiol; 2003 Apr; 41(7):1183-94. PubMed ID: 12679220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The discovery of aspirin's antithrombotic effects.
    Miner J; Hoffhines A
    Tex Heart Inst J; 2007; 34(2):179-86. PubMed ID: 17622365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.